|Dr. Cameron Durrant M.B.A., M.D., MBA||Chairman & CEO||784.5k||N/A||1960|
|Mr. Timothy Morris CPA, CPA||CFO & COO||66k||N/A||1962|
|Mr. David L. Tousley CPA, M.B.A., CPA||Chief Accounting & Admin. Officer, Corp. Sec. and Treasurer||N/A||N/A||1956|
|Dr. Dale Chappell M.B.A., M.D., MBA||Chief Scientific Officer||N/A||N/A||1970|
|Dr. Tarek Sahmoud||Chief Medical Officer||N/A||N/A||N/A|
|Dr. Omar Ahmed Pharm.D.||Sr. VP of Clinical, Medical & Scientific Affairs||N/A||N/A||N/A|
|Mr. Robert Atwill M.B.A.||Head of Asia-Pacific||N/A||N/A||N/A|
|Mr. Edward P. Jordan M.B.A.||Chief Commercial Officer||N/A||N/A||1968|
Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.
Humanigen, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.